MANGOCEUTICALS, Inc. (MGRX) intrinsic value & 10-year financials
MANGOCEUTICALS, Inc. (MGRX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 5 fiscal years revenue grew 270.9% a year to $456.0K, with an average return on invested capital of -5900.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.29
- Market cap
- $2.9M
- Revenue (FY2025)
- $456.0K
- Revenue growth (5-yr CAGR)
- 270.9%
- ROIC (10-yr avg)
- -5900.1%
- Free cash flow (FY2025)
- —
MGRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $456.0K | -$20.6M | -$2.17 | — | -3954.3% | -141.6% |
| FY2024 | $615.9K | -$8.7M | -$0.97 | — | -1294.4% | -8644.9% |
| FY2023 | $731.5K | -$9.2M | -$0.11 | -$7.0M | -1260.3% | -11475.4% |
| FY2022 | $8.9K | -$2.0M | -$0.04 | -$1.4M | -22279.7% | -3338.4% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MANGOCEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MANGOCEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -94.1% ROIC.
MANGOCEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, MANGOCEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-72.08 per share.